Program
pitolisant
Also written as “Pitolisant”, “Open-label Pitolisant” and “Pitolisant Oral Tablet”.
Its studies are mostly in Prader-Willi Syndrome · Idiopathic Hypersomnia · Myotonic Dystrophy · Disorders of Excessive Somnolence · Diabetes Mellitus, Type 1, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Harmony Biosciences | 62 open or running | phase 3since Dec 1, 2021 | Jan 29, 2020 | Apr 2027phase 3 · NCT06366464 |
| Citrine Medicine | 10 open or running | phase 3since Jan 24, 2022 | Jan 24, 2022 | none ahead |
| High Point Clinical Trials Center | 10 open or running | phase 1since Jul 17, 2019 | Jul 17, 2019 | none ahead |
Also a collaborator on its studies: ferox-therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 17, 2019First study: phase 1 study in Diabetes Mellitus, Type 1New to High Point Clinical Trials CenterHigh Point Clinical Trials Center · NCT04026750 · 5 enrolled · United States
- Jan 29, 2020Harmony Biosciences's first study: phase 2 study in Prader-Willi SyndromeNew to Harmony BiosciencesHarmony Biosciences · NCT04257929 · 65 enrolled · United States
- May 10, 2021Phase 2 study in Myotonic DystrophyHarmony Biosciences · NCT04886518 · 30 enrolled · United States, Canada
- Dec 1, 2021Phase 3 study in Idiopathic HypersomniaHarmony Biosciences · NCT05156047 · 214 enrolled · United States
- Jan 24, 2022Citrine Medicine's first study: phase 3 study in Disorders of Excessive SomnolenceNew to Citrine MedicineCitrine Medicine · NCT05223166 · 240 enrolled · China
- Jul 11, 2022Phase 3 study in Idiopathic HypersomniaHarmony Biosciences · NCT05458128 · 119 enrolled · United States
- Oct 9, 2023Phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT06366464 · 134 planned · United States, Australia, Belgium and more
- Oct 20, 2025Phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT07219485 · 150 planned · United States
Ahead
- Apr 2027Primary completion: phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT06366464
- Aug 2030Primary completion: phase 3 study in Prader-Willi SyndromeHarmony Biosciences · NCT07219485
TargetBeta
“Histamine H3 receptor inverse agonist; Histamine H3 receptor inverse agonist”ChEMBL 37, by rule
Other programs on HRH3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| samelisantrule | suven-life-sciences-limited | phase 3 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07219485Prader-Willi Syndrome · United States | 3 | By invitation | Harmony Biosciences | Aug 2030 | 150 |
| NCT06366464Prader-Willi Syndrome · United States, Australia, Belgium and more | 3 | Recruiting | Harmony Biosciences | Apr 2027 | 134 |
| NCT05458128Idiopathic Hypersomnia · United States | 3 | Completed | Harmony Biosciences | Oct 1, 2025 | 119 |
| NCT05223166Disorders of Excessive Somnolence · China | 3 | Completed | Citrine Medicine | Jul 18, 2023 | 240 |
| NCT05156047Idiopathic Hypersomnia · United States | 3 | Completed | Harmony Biosciences | Sep 8, 2023 | 214 |
| NCT04886518Myotonic Dystrophy · United States, Canada | 2 | Completed | Harmony Biosciences | Oct 6, 2023 | 30 |
| NCT04257929Prader-Willi Syndrome · United States | 2 | Completed | Harmony Biosciences | Aug 17, 2022 | 65 |
| NCT04026750Diabetes Mellitus, Type 1 · United States | 1 | Terminated | High Point Clinical Trials Center | Feb 16, 2020 | 5 |
How it is read
Names in the registry
- “Pitolisant”, 4 entries
- “Open-label Pitolisant”, 1 entry
- “Pitolisant Oral Tablet”, 1 entry
- “Pitolisant tablet”, 1 entry
- “Pitolisant oral tablets”, 1 entry
Conditions, from the studies’ own filings
- Prader-Willi Syndrome, 3 studies
- Idiopathic Hypersomnia, 2 studies
- Myotonic Dystrophy, 1 study
- Disorders of Excessive Somnolence, 1 study
- Diabetes Mellitus, Type 1, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.